Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tipranavir.

Greg L Plosker1, David P Figgitt

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 31, 2003
PubMed
Summary
This summary is machine-generated.

Tipranavir offers a superior resistance profile against HIV-1 protease mutations compared to older inhibitors. Clinical trials show tipranavir-based therapy achieves sustained viral suppression in treatment-experienced patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Asenapine: A Review in Schizophrenia.

CNS drugs·2016
Same author

AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.

Drugs·2015
Same author

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.

Drugs·2015
Same author

Acamprosate: A Review of Its Use in Alcohol Dependence.

Drugs·2015
Same author

Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain.

Clinical drug investigation·2015
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Antiviral drug development
  • HIV/AIDS research
  • Molecular virology

Background:

  • Traditional peptidomimetic protease inhibitors face reduced efficacy with increasing HIV-1 protease gene mutations.
  • HIV-1 protease inhibitor resistance-associated mutations (PRAMs) significantly impact treatment outcomes.
  • Tipranavir represents a non-peptidic HIV-1 protease inhibitor designed for improved resistance profiles.

Purpose of the Study:

  • To evaluate the efficacy and resistance profile of tipranavir in HIV-1 infected patients.
  • To assess tipranavir's potential in managing multi-drug resistant HIV infection.
  • To compare tipranavir-based regimens with other protease inhibitor therapies.

Main Methods:

  • Phase II and III clinical trials involving HIV-1 infected patients with prior protease inhibitor exposure.

Related Experiment Videos

  • Dose-finding studies assessing viral load reduction during functional monotherapy.
  • Comparative efficacy trials of tipranavir/ritonavir against other ritonavir-boosted protease inhibitors.

    • Main Results:

    • Tipranavir requires a significantly higher number of mutations (16-20) to confer resistance compared to older inhibitors.
    • Sustained viral suppression (>48 weeks) observed in a Phase II trial of tipranavir-based therapy.
    • Potent virological reduction demonstrated in heavily pretreated patients with extensive protease gene mutations.

    Conclusions:

    • Tipranavir exhibits a promising resistance profile, potentially overcoming limitations of existing protease inhibitors.
    • Tipranavir-based regimens are being investigated for efficacy in multi-drug resistant HIV infection.
    • Tipranavir is generally well-tolerated, with gastrointestinal disturbances being the most common adverse events.